Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO)

Harvey D. White(University of Auckland), Burt Adelman(Unknown), W. Stewart Hillis(Biogen (United States)), Yoseph Shalev(Biogen (United States)), John M. Maraganore(Biogen (United States)), Rory Collins(University of Oxford), John K. French(Biogen (United States)), Melissa A. Brown(Wellcome Centre for Cell-Matrix Research), Ravi Nair(Biogen (United States)), A.A.J. Adgey(Biogen (United States)), M Frey(Biogen (United States)), Philip E. Aylward(Flinders Medical Centre)
Circulation
October 7, 1997
10.1161/01.cir.96.7.2155
Cited by 232

Related Papers

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
|The Lancet|2003|3.8k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
|The Lancet|2005|2.9k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k